

# Hydrotherapy May Offer Bowel Prep Advantages

BY BETSY BATES  
Los Angeles Bureau

LAS VEGAS — The safety, efficacy, and—perhaps most important—tolerability of bowel preparation for colonoscopy came under intense scrutiny at the annual meeting of the American College of Gastroenterology.

“We desperately need to have one regimen that gives us the ideal preparation,” said Dr. Douglas K. Rex, professor of medicine and director of endoscopy at Indiana University Hospital in Indianapolis.

“Bowel preparation is a very, very big deal,” he continued during the Emily Couric Annual Lecture at the meeting. “We already know it’s the thing patients complain about most.”

The problems with bowel preparation are twofold: People referred for colonoscopy often don’t get it done because they expect the preparation to be inconvenient and uncomfortable, and the difficulties of currently available methods of bowel

**Hydrotherapy received significantly higher colon cleansing quality scores for every area of the colon than the sodium phosphate or PEG-Es methods.**

preparation often lead to incomplete cleansing. The latter problem leads to inadequate visualization in up to 25% of colonoscopies, Dr. Rex added.

“The costs of that over time are enormous,” he said.

One method is the use of aqueous sodium phosphate solutions, which have proven efficacious and reasonably tolerable. But there is some concern about their safety because of problems with electrolyte imbalances, dehydration, and renal failure, he explained.

Polyethylene glycol-electrolyte (PEG-ES) lavage preparations are considered safer but are not as well tolerated, he said.

A third method, hydrotherapy, may offer a reasonable alternative, if early studies can be replicated, he said. In a 45-minute procedure immediately preceding colonoscopy, a trained technician uses a pressure-controlled device to lavage the colon with a constant flow of warm water.

In a study presented at the meeting, the hydrotherapy method was compared with two other methods: 4 L of PEG-ES and aqueous sodium phosphate given in two doses. Patients aged 38-80 years (average age, 61 years) were randomized to one of the three procedures.

Hydrotherapy received significantly higher colon cleansing quality scores for every area of the colon (right, transverse, and left) than the sodium phosphate or PEG-Es methods, reported Dr. Joseph J. Fiorito of Danbury (Conn.) Hospital. The ratings were completed by endoscopists blinded to the preparation method used. For example, in the right colon, the quality of cleansing was rated as “good” in 32 of 52 patients (62%) who received aqueous sodium phosphate, 27 of 55 patients (49%) who took PEG-ES, and 49 of 53

(92%) who underwent hydrotherapy.

Patients who received hydrotherapy reported higher scores for ease, convenience, and comfort than patients who underwent the other methods. When asked if they would prefer a different bowel cleansing method if they were to undergo another colonoscopy, 1 of 53 (2%) who had hydrotherapy cleansing said yes, compared with 25 of 52 (48%) of the aqueous sodium phosphate group and 33 of 55 (60%) who had PEG-ES.

One patient (not included in the final analyses) did not complete the hydrotherapy procedure because of discomfort.

Dr. Fiorito said that the patients in the study were not charged for colonoscopy preparation, but that the estimated cost of hydrotherapy ranges from \$35 to \$75. “It would be nice to have insurance companies or Medicare to look at this as an alternative method of preparation,” he said.

Hydrotherapy Inc. of Las Vegas funded the study.

Another study, which was presented as a poster at the meeting, compared a new, 32-tablet form of sodium phosphate preparation with a bowel preparation kit containing 2 L of PEG and bisacodyl tablets. The study found that less irrigation was necessary during colonoscopy and more polyps were identified when subjects took the tablets. The new tablet formulation, marketed as OsmoPrep, is made by Salix Pharmaceuticals Inc. of Morrisville, N.C., which sponsored the study. ■

Help your patients stay

**AWAKE, ALERT, and ENGAGED**

Structurally distinct from amphetamines<sup>1</sup>

No effect on sleep when sleep is desired\*<sup>1,2</sup>

Favorable safety profile

**PROVIGIL**<sup>®</sup>  
(MODAFINIL)<sup>®</sup>  
Tablets

PROVIGIL is indicated to improve wakefulness in patients with excessive sleepiness (ES) associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS), and shift work sleep disorder (SWSD).

In OSAHS, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction.

**Important Information for Physicians**

Patients with abnormal levels of sleepiness who take PROVIGIL should be advised that their level of wakefulness may not return to normal. Patients with excessive sleepiness, including those taking PROVIGIL, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.

In clinical trials, PROVIGIL was generally well tolerated. The most frequently reported adverse events (≥5%) were headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspepsia. Most adverse events were mild to moderate. PROVIGIL may interact with drugs that inhibit, induce, or are metabolized by cytochrome P450 isoenzymes.

For more information, visit [www.PROVIGIL.com](http://www.PROVIGIL.com) or call 1-800-896-5855.

Please see brief summary of prescribing information for PROVIGIL on next page.

\*No change from baseline to final visit in sleep efficiency.

References: 1. PROVIGIL full Prescribing Information. 2. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. *Sleep*. 2005;28:464-471.

**Cephalon** © 2006 Cephalon, Inc. PRO802  
Sep 2006 All rights reserved. Printed in USA.

